Coherus BioSciences Inc
(NAS:CHRS)
$
1.78
0.02 (1.14%)
Market Cap: 204.21 Mil
Enterprise Value: 423.31 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 42/100 Coherus BioSciences Inc at Bank of America Healthcare Conference Transcript
May 12, 2022 / 07:00PM GMT
Release Date Price:
$7.59
(-2.06%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
Our last presentation slot of the Bank of America Annual Healthcare Conference. My name is Jason Gerberry, I'm one of the biotech and spec pharma analyst at BofA. And I'm joined by Coherus Biosciences and CEO, Denny Lanfear; and Theresa Lavallee, Chief Development Officer. So first off, thanks for joining us in the last slot of the day.
Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO
Thank you. Thank you very, very much, Jason, for having us today, and we're happy to come to the conference here in Vegas.
Questions & Answers
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
Great. Great. So maybe at a high level, can you talk a little bit about the evolution of Coherus and the strategy, right, initially very biosimilar focus? Now you've got the IO assets and you're evolving. And I think kind of like a route commonality amongst everything is there's
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot